Nivolumab-induced plaque morphea in a malign melanoma patient


Acar A. , Oraloglu G., Yaman B. , Karaarslan I.

JOURNAL OF COSMETIC DERMATOLOGY, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2020
  • Doi Number: 10.1111/jocd.13914
  • Title of Journal : JOURNAL OF COSMETIC DERMATOLOGY

Abstract

Background Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melanoma, lung, renal, head and neck, colorectal, hepatocellular cancers, and special cases of Hodgkin lymphoma.